The relationship between defects in lymphocyte production of transforming growth factor-B1 in systemic lupus erythematosus and disease activity or severity

Lupus

Volumn 8, Issue 2, 1999, Pages 90-94

  Ohtsuka, K ^a   Gray, J D ^a   Stimmler, M M ^a   Horwitz, D A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cytokines; Systemic lupus erythematosus; Transforming growth factor beta

Indexed keywords

CD2 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; LYMPHOCYTE; MALE; METABOLIC ACTIVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032911090     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678847489     Document Type: Article

References (17)

1. Horwitz DA, Stohl W, Gray JD. T lymphocytes, natural killer cells, cytokines, and immune regulation. Dubois Lupus Erythematosus, 5th edn. Hahn BH and Wallace D (eds). Williams and Wilkins: Baltimore, 1997, pp155-194.
2. + T and NK cells. J Exp Med 1994; 180: 1937-1942.
3. Flaumenhaft R, Kojima S, Abe M, Rifkin DB. Activation of latent transforming growth factor β. Adv Pharmacol 1993; 24: 51-76.
4. + T cells, IL-2, and NK cell-derived TGF-β, contrasting effects of anti-CD2 and anti-CD3. J Immunol 1998; 160: 2248-2254.
5. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol 1998; 16: 137-161.
6. Ohtsuka K at al. Decreased production of TGF-β by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998; 160: 2539-2545.
7. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
8. Arnett FC et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumtoid arthritis. Arthritis Rheum 1988; 31: 315-324.
9. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systemic for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
10. Bombardier C et al. Derivation of the SLEDAI, a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
11. Llorente et al. Spontaneous production of IL-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Network 1993; 4: 421-427.
12. Houssiau FA et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 393-395.
13. Hagiwara E, Gourley MF, Lee S, Klinman DM. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-y-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385.
14. Moore KW et al. Interleukin-10. Ann Rev Immunol 1993; 11: 165-190.
15. + T cells by transforming growth-β1. J Immunol 1991; 151: 668-677.
16. Lee HM, Rich S. Co-stimulation of T cell proliferation by transforming growth factor-β1. J Immunol 1991; 147: 1127-1133.
17. Cerwenka A, Bevec D, Majdic O, Knapp W. TGF-β1 is a potent inducer of human effector T cells. J Immunol 1994; 153: 4367-4377.